Immunologic response to mistletoe extract (Viscum album L.) after conventional treatment in patients with operable breast cancer

Journal of Breast Cancer

Volumn 13, Issue 1, 2010, Pages 14-18

  Son, Gil Soo ^a   Ryu, Woo Sang ^a   Kim, Hoon Yub ^a   Woo, Sang Uk ^a   Park, Kyong Hwa ^a   Bae, Jeoung Won ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Immunology; Mistletoe; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; VISCUM ALBUM EXTRACT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; MINIMALLY INVASIVE SURGERY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 77953196147     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2010.13.1.14     Document Type: Article

References (24)

1. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107: 262-7.
2. Bussing A. Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2006;56:508-15.
3. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer: a systematic review on controlled clinical trials. Eur J Med Res 2003;8:109-19.
4. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007;12:103-19.
5. Lyu SY, Park WB. Mistletoe lectin (Viscum album coloratum) modulates proliferation and cytokine expressions in murine splenocytes. J Biochem Mol Biol 2006;39:662-70.
6. Sulizeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993;60:247-67.
7. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
8. Hajto T, Hostanska K, Gabius HJ. Modulatory potency of the betagalactoside- specific lectin from Mistletoe Extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989; 49:4803-8.
9. Kovacs E. Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother 2000;54:305-10.
10. Gardin NE. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Phytother Res 2009;23:407-11.
11. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000;7:187-90.
12. Knüpfer H, Preiss R. Significance of interleukin-6 in breast cancer (review). Breast Cancer Res Treat 2007;102:129-35.
13. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000;7:124-9.
14. Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Blaese RM. Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 1992;52:6020-4.
15. Sun WH, Kreisle RA, Phillips AW, Ershler WB. In vivo and in vitro characteristics of interleukin 6 transfected B16 melanoma cells. Cancer Res 1992;52:5412-5.
16. Xiao B, Jing B, Zhang YL, Zhou DY, Zhang WD. Tumor growth inhibition effect of hIL-6 on colon cancer cells transfected with the target gene by retroviral vector. World J Gastroenterol 2000;6:89-92.
17. Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 1989;143:1206-9.
18. Ishiguro H, Kishimoto T, Furuya M, Nagai Y, Watanabe T, Ishikura H. Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immune-compromised hosts. Cancer Immunol Immunother 2005; 54:1191-9.
19. Elluru SR, van Huyen JP, Delignat S, Kazatchkine MD, Friboulet A, Kaveri SV, et al. Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 2008; 8:161.
20. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007;96:41-101.
21. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
22. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996;93:7673-8.
23. Schreiber RD, Celada A, Buchmeier N. The role of interferon-gamma in the induction of activated macrophages. Ann Inst Pasteur Immunol 1986;137:203-6.
24. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000;30: 985-92.